BMS settles Plavix deal probe
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb has agreed to pay a civil fine of $2.1 million to end a US Federal Trade Commission probe into the company's failed 2006 attempt to negotiate a favourable drug patent settlement for Plavix (clopidogrel) with Apotex.